Schrodinger

Schrodinger shares surged during regular trading, closing at USD 17.21, up 5.00%, driven by a ~USD 57 million milestone payment following Eli Lilly's ~USD 1.7 billion acquisition of Ajax Therapeutics, a key partner. The stock rallied from a pre-market low of USD 16.30 to a session high of USD 17.21, with a regular-session range of USD 16.69 to USD 17.21. Despite Q1 2026 revenue falling 1.62% YoY to USD 58.59 million and a net loss of USD 60.03 million, the stock has climbed above its 20-day (USD 15.45) and 60-day (USD 13.62) moving averages, remaining 27.54% below its 52-week high of USD 23.75. However, the company remains unprofitable with a negative P/E ratio of 12.43, underscoring its development-stage profile.